Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes

• US 6,832,114 B1
• Filed: 11/06/2001
• Issued: 12/14/2004
• Est. Priority Date: 11/21/2000
• Status: Expired due to Fees

• Current Assignee: Boston Scientific Neuromodulation Corporation (Boston Scientific Corporation)
• Original Assignee: Advanced Bionics Corporation (Sonova Holding AG)
• Inventors: Whitehurst, Todd K., McGivern, James P.
• Primary Examiner(s): MANUEL, GEORGE C
• Application Number:
  US09/993,084
• Time in Patent Office: 1,134 Days
• Field of Search: 607/40, 607/133, 600/554, 600/300, 600/301, 128/897-899, 128/920, 604/891.1, 604/890.1, 604/65-67
• US Class Current: 607/40
• CPC Class Codes: A61N 1/326 for promoting growth of cells, e.g. bone cells

Abstract

Systems and methods for introducing one or more stimulating drugs and/or applying electrical stimulation to the pancreas and/or nerve fibers innervating the pancreas to treat or prevent diabetes and/or to modulate pancreatic endocrine secretions uses at least one system control unit (SCU) producing electrical pulses delivered via electrodes and/or producing drug infusion pulses, wherein the stimulating drug(s) are delivered via one or more pumps and infusion outlets.

Claims

1. A method of modulating pancreatic endocrine secretions of a patient, comprising:

implanting at least one system control unit in the body of a patient, wherein the at least one unit controls the delivery of at least one stimulus to at least one type of pancreatic cell affecting pancreatic endocrine secretions; and

applying the at least one stimulus to the at least one type of pancreatic cell in order to hyperpolarize the at least one type of pancreatic cell and thereby modulate at least one pancreatic endocrine secretion;

wherein the at least one type of pancreatic cell is an alpha cell and wherein the hyperpolarization inhibits secretion of glucagon.

2. A method of modulating pancreatic endocrine secretions of a patient, comprising:

implanting at least one system control unit in the body of a patient, wherein the at least one unit controls the delivery of at least one stimulus to at least one type of pancreatic cell affecting pancreatic endocrine secretions; and

applying the at least one stimulus to the at least one type of pancreatic cell in order to hyperpolarize the at least one type of pancreatic cell and thereby modulate at least one pancreatic endocrine secretion;

wherein the at least one type of pancreatic cell is a delta cell and wherein the hyperpolarization inhibits secretion of somatostatin.

3. A method of modulating pancreatic endocrine secretions of a patient, comprising:

implanting at least one system control unit in the body of a patient, wherein the at least one unit controls the delivery of at least one stimulus to at least one type of pancreatic cell affecting pancreatic endocrine secretions; and

applying the at least one stimulus to the at least one type of pancreatic cell in order to depolarize the at least one type of pancreatic cell to thereby increase secretion of a substance that inhibits insulin secretion.

4. The method of claim 3, wherein the at least one type of pancreatic cell is an alpha cell and wherein the depolarization increases secretion of glucagon.

5. The method of claim 3 wherein the at least one type of pancreatic cell is a delta cell and wherein the depolarization increases secretion of somatostatin.

6. A method of modulating pancreatic endocrine secretions of a patient, comprising:

implanting at least one system control unit in the body of a patient, wherein the at least one unit controls the delivery of simulation to at least one parasympathetic tissue innervating the pancreas; and

applying the stimulation to the at least one parasympathetic tissue in order to minimize stimulation of gastrointestinal structures and the heart while maximizing stimulation of pancreatic beta cells, whereby insulin secretion is modulated.

7. The method of claim 6 wherein the stimulation is applied to at least one of the posterior gastric, anterior gastric, celiac, and hepatic branches of the vagus nerve.

8. The method of claim 6 further comprising applying the stimulation to the at least one parasympathetic tissue in order to increase insulin secretion.

9. The method of claim 8 wherein the at least one system control unit is connected to at least two electrodes, and wherein the stimulation is electrical stimulation applied via the at least two electrodes at a frequency of about 3-12 Hz.

10. The method of claim 6 further comprising applying the simulation to the at least one parasympathetic tissue in order to decrease insulin secretion.

11. The method of claim 10 wherein the at least one system control unit is connected to at least two electrodes, and wherein the stimulation is electrical stimulation applied via the at least two electrodes at a frequency of greater than about 50 Hz.

12. The method of claim 10 wherein the simulation is drug simulation and wherein at least one of a cholinoceptor-blocking medication and an autonomic ganglion-blocking medication is applied to the parasympathetic tissue.

13. A method of modulating pancreatic endocrine secretions of a patient, comprising:

implanting at least one system control unit in the body of a patient, wherein the at least one unit controls the delivery of stimulation to at least one sympathetic tissue innervating the pancreas; and

applying the stimulation to the at least one sympathetic tissue in order to modulate at least one pancreatic endocrine secretion;

wherein the at least one sympathetic tissue is at least one of the ganglia of the paraspinal sympathetic trunks, cellac ganglia, aorticorenal ganglia, super mesenteric ganglion, inferior mesenteric ganglion, phrenic ganglion, left greater splanchnic nerve, left lesser splanchnic nerve, left least splanchnic nerve, right greater splanchnic nerve, right lesser splanchnic nerve, and right least splanchnic nerve.

14. The method of claim 13 further comprising sensing a condition and using the sensed condition to automatically determine the stimulation to apply.

15. The method of claim 13 wherein the stimulation inhibits sympathetic input to the pancreas, whereby glucagon secretion is reduced.

16. The method of claim 15 wherein the at least one system control unit is connected to at least two electrodes, and wherein the stimulation is electrical stimulation delivered via the at least two electrodes at a frequency of greater than about 50 Hz.

17. The method of claim 15 wherein the stimulation is drug stimulation and wherein at least one of an adrenoceptor antagonist medication and an autonomic ganglion-blocking medication is applied to the sympathetic tissue.

18. The method of claim 13 wherein the stimulation excites sympathetic input to the pancreas, whereby glucagon secretion is increased.

19. The method of claim 18 wherein the at least one system control unit is connected to at least two electrodes, and wherein the stimulation is electrical stimulation delivered via the at least two electrodes at a frequency of less than about 100 Hz.

20. The method of claim 18 wherein the stimulation is drug stimulation and wherein at least one of an adrenoceptor-activating medication and a sympathomimetic medication is applied to the sympathetic tissue.

21. A method of modulating pancreatic endocrine secretions of a patient, comprising:

implanting at least one system control unit in the body of a patient, wherein the at least one unit controls the delivery of drug stimulation to at least one area affecting pancreatic endocrine secretions; and

applying the drug stimulation to the at least one area in order to modulate at least one pancreatic endocrine secretion;

wherein the at least one system control unit is connected to at least one catheter, and wherein the stimulating drug is applied via the at least one catheter to at least one pancreatic islet or graft to increase insulin secretion, and wherein the drug is at least one of K+, Ca++, arginine, lysine, acetylcholine, a cholinergic agonist, a beta-adrenergic agonist, an alpha-adrenergic antagonist, glucagon-like peptide 1, gastric inhibitory peptide, secretin, cholecystokinin, and a beta-3-agonist.

22. The method of claim 21 further comprising sensing a condition and using the sensed condition to automatically determine the stimulation to apply.

23. A method of modulating pancreatic endocrine secretions of a patient, comprising:

implanting at least one system control unit in the body of a patient, wherein the at least one unit controls the delivery of drug stimulation to at least one area affecting pancreatic endocrine secretions; and

applying the drug stimulation to the at least one area in order to modulate at least one pancreatic endocrine secretion;

wherein the at least one system control unit is connected to at least one catheter, and wherein the stimulating drug is applied via the at least one catheter to at least one pancreatic islet or graft to inhibit insulin secretion, and wherein the drug is at least one of an alpha-adrenergic agonist, a chollnergic antagonist, a beta-adrenergic antagonist, galanic, oancreastatin, and leptin.

24. The method of claim 23 further comprising sensing a condition and using the sensed condition to automatically determine the stimulation to apply.

25. A method of modulating pancreatic endocrine secretions of a patient, comprising:

implanting at least one system control unit in the body of a patient, wherein the at least one unit controls the delivery of drug stimulation to at least one area affecting pancreatic endocrine secretions; and

applying the drug stimulation to the at least one area in order to modulate at least one pancreatic endocrine secretion;

wherein the at least one system control unit is connected to at least one catheter, and wherein the stimulating drug is applied via the at least one catheter to at least one pancreatic islet or graft to increase glucagon secretion, and wherein the drug is at least one of an alpha-adrenergic agonist, arginine, and alanine.

26. The method of claim 25 further comprising sensing a condition and using the sensed condition to automatically determine the stimulation to apply.

27. A method of modulating pancreatic endocrine secretions of a patient, comprising:

implanting at least one system control unit in the body of a patient, wherein the at least one unit controls the delivery of drug stimulation to at least one area effecting pancreatic endocrine secretions; and

applying the drug stimulation to the at least one area in order to modulate at least one pancreatic endocrine secretion;

wherein the at least one system control unit is connected to at least one catheter, and wherein the stimulating drug is applied via the at least one catheter to at least one pancreatic islet or graft to inhibit glucagon secretion, and wherein the drug is at least one of an alpha-adrenergic antagonist, glucose, and insulin.

28. The method of claim 27 further comprising sensing a condition and using the sensed condition to automatically determine the stimulation to apply.